Abstracts tagged "Hepatic disorders"

Abstract Number: 1513 • 2015 ACR/ARHP Annual Meeting
Reactivation of Hepatitis B-Infection in German Patients with Inflammatory Rheumatic Diseases Treated with Biologics – a Monocentric Analysis Involving 1107 Patients
Eva Christina Scharbatke¹, Sonja Kreissl-Kemmer², Hans-Peter Tony³, Marc Schmalzing⁴ and Andreas Geier², ¹Rheumatology/Immunology, University hospital Wuerzburg, Wuerzburg, Germany, ²Hepatology, University hospital Wuerzburg, Wuerzburg, Germany, ³University Hospital Würzburg, Würzburg, Germany, ⁴Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Hepatitis B virus (HBV) reactivation is a common complication of immunosuppressive treatment in countries with a high prevalence of HBV infection. Biologics – and…
Abstract Number: 2752 • 2014 ACR/ARHP Annual Meeting
Budd-Chiari Syndrome Due to Behçet’s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome
Emire Seyahi¹, Erkan Caglar², Serdal Ugurlu¹, Fatih Kantarci³, Vedat Hamuryudan¹, Abdullah Sonsuz⁴, Melike Melikoglu⁵, Sebahattin Yurdakul¹ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Gastroenterology, Department of Internal Medicine, Bakirkoy Research and Training Hospital, Istanbul, Turkey, ³Department of Radiology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, ⁴Department of Gastroenterology, Cerrahpasa Medical Faculty of Istanbul Universit, Cerrahpasa Medical Faculty of Istanbul University, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose Behçet’s syndrome (BS) is a well recognized cause of Budd–Chiari syndrome (BCS), however, information about its clinical characteristics and outcome is limited. We had…
Abstract Number: 1821 • 2012 ACR/ARHP Annual Meeting
Clinical Predictors of Methotrexate-Induced Liver Enzyme Elevation in Patients with Rheumatoid Arthritis in an Electronic Medical Record
Monica Ramirez¹, Bing Lu¹, Michelle A. Frits², Anne H. Fossel³, Katherine P. Liao⁴, Robert M. Plenge⁵, Jonathan S. Coblyn⁶, Nancy A. Shadick⁷ and Elizabeth W. Karlson⁴, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology/Immunology, Brigham & Womens Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Methotrexate (MTX) use for the treatment of rheumatoid arthritis (RA) has been associated with hepatotoxicity, and requires monitoring of liver transaminases. However, elevations in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].